ORPHENADRINE CITRATE Drug Interactions
Also known as: Orphenadrine Citrate
Orphenadrine Citrate is a prescription medication used to help relieve muscle discomfort and pain. It works by relaxing muscles and reducing stiffness, often prescribed alongside rest and physical therapy for acute muscle conditions.ORPHENADRINE CITRATE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience profound sedation, respiratory depression, coma, and even death. Other symptoms include dizziness, confusion, impaired psychomotor function, and hypotension. The risk of falls and accidental injury is significantly increased.
Mechanism
Buprenorphine, an opioid partial agonist, causes central nervous system (CNS) depression through its activity at mu-opioid receptors. Orphenadrine citrate, a skeletal muscle relaxant with anticholinergic properties, also exerts CNS depressant effects. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of buprenorphine and orphenadrine citrate if possible. If co-administration is necessary, use the lowest effective doses and monitor patients closely for signs of CNS depression, particularly respiratory depression and sedation. Advise patients against operating heavy machinery or driving and educate them on the risks.
Patients may experience severe respiratory depression, including hypoventilation and apnea, profound sedation, somnolence, and decreased level of consciousness. Other potential effects include dizziness, impaired psychomotor function, and increased risk of falls. In severe cases, this can lead to coma and death.
Mechanism
Both fentanyl, an opioid analgesic, and orphenadrine citrate, a skeletal muscle relaxant with anticholinergic and antihistaminic properties, exert central nervous system (CNS) depressant effects. The co-administration leads to an additive pharmacological effect on GABAergic and other inhibitory neurotransmitter systems, significantly enhancing CNS depression. This synergistic action increases the risk of profound respiratory depression and sedation.
Clinical Management
Avoid concomitant use of fentanyl and orphenadrine citrate if possible. If co-administration is unavoidable, reduce the starting dose of one or both medications, particularly the opioid, and monitor patients closely for signs of respiratory depression and sedation. Educate patients on the risks and advise them to avoid activities requiring mental alertness, such as driving or operating heavy machinery.
This interaction can lead to severe adverse effects including profound sedation, respiratory depression, hypotension, and psychomotor impairment. Patients may experience dizziness, confusion, slowed breathing, and difficulty with coordination, increasing the risk of falls and accidental injury.
Mechanism
Oxycodone, an opioid analgesic, primarily acts on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and CNS depression. Orphenadrine citrate, an anticholinergic muscle relaxant, also has CNS depressant effects. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants.
Patients may experience profound sedation, dizziness, confusion, and impaired motor coordination, increasing the risk of falls and accidents. The most serious clinical effect is life-threatening respiratory depression, which can lead to hypoxia, coma, and death. Other effects include hypotension and severe constipation.
Mechanism
Both morphine (an opioid analgesic) and orphenadrine (a skeletal muscle relaxant with anticholinergic properties) exert central nervous system (CNS) depressant effects. The co-administration leads to an additive depressant effect on the CNS, intensifying sedation, respiratory depression, and psychomotor impairment. Orphenadrine's anticholinergic effects can also contribute to confusion and delirium, particularly in susceptible patients.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, patients should be closely monitored for signs of CNS and respiratory depression, especially during initiation or dose adjustments of either drug. Lower doses of both medications should be considered, and patients should be educated on the risks and advised against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can increase the risk of falls, accidents, and life-threatening respiratory compromise. Symptoms of anticholinergic toxicity such as confusion, delirium, and urinary retention may also be exacerbated.
Mechanism
Tramadol is an opioid analgesic that primarily acts on mu-opioid receptors and also inhibits reuptake of norepinephrine and serotonin. Orphenadrine is a skeletal muscle relaxant with anticholinergic and antihistaminic properties that contributes to central nervous system (CNS) depression. The co-administration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of tramadol and orphenadrine if possible. If co-administration is unavoidable, reduce the starting dose of one or both medications, particularly in elderly or debilitated patients. Monitor patients closely for signs of respiratory depression, excessive sedation, and altered mental status, and advise them against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and severe constipation may also occur.
Mechanism
Codeine sulfate, an opioid analgesic, produces central nervous system (CNS) depression through its agonistic effects on mu-opioid receptors. Orphenadrine citrate, an anticholinergic and skeletal muscle relaxant, also causes CNS depression through its central anticholinergic and sedative properties. The concurrent use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the significant risk of additive CNS depression and respiratory compromise. If co-administration is unavoidable, initiate therapy with the lowest effective doses of both drugs and monitor patients closely for signs of sedation and respiratory depression. Educate patients about the risks and advise them to avoid activities requiring mental alertness, such as driving.
Patients may experience profound sedation, respiratory depression, coma, and even death. Other clinical manifestations include dizziness, confusion, impaired psychomotor function, and hypotension. The risk is heightened in elderly patients or those with pre-existing respiratory compromise.
Mechanism
Methadone is a potent opioid agonist that produces central nervous system (CNS) depression through mu-opioid receptor activation. Orphenadrine citrate, an anticholinergic and antihistaminic agent with muscle relaxant properties, also exerts CNS depressant effects. The co-administration of these agents leads to an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and orphenadrine due to the significant risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dose of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-pharmacological therapies or muscle relaxants with less CNS depressant effects if possible.
Patients may experience profound sedation, respiratory depression, hypotension, coma, and even death. Impaired psychomotor function, dizziness, and confusion are also common. The risk of these adverse effects is significantly increased when both drugs are used concurrently.
Mechanism
Hydromorphone is an opioid analgesic that primarily acts on mu-opioid receptors in the central nervous system (CNS), leading to dose-dependent CNS depression, including respiratory depression and sedation. Orphenadrine is an anticholinergic agent with muscle relaxant properties that also exerts significant CNS depressant effects. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of hydromorphone and orphenadrine due to the high risk of additive CNS depression. If co-administration is unavoidable, reduce the starting dose of one or both medications, monitor patients closely for signs of respiratory depression and sedation, and limit the duration of therapy. Educate patients about the risks and advise them to avoid driving or operating heavy machinery.
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to increased risk of falls, accidental injury, and potentially life-threatening respiratory compromise, especially in opioid-naive individuals or those with underlying respiratory conditions.
Mechanism
Oxymorphone is an opioid agonist that produces central nervous system (CNS) depression through its action on mu-opioid receptors. Orphenadrine is an anticholinergic muscle relaxant with significant CNS depressant and sedative properties. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxymorphone and orphenadrine if possible. If co-administration is necessary, initiate both medications at the lowest effective dose and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience severe respiratory depression, profound sedation, coma, and even death. Other clinical effects include dizziness, impaired psychomotor function, confusion, and hypotension, which significantly increase the risk of falls and accidental injury.
Mechanism
Tapentadol is an opioid analgesic with mu-opioid receptor agonist and norepinephrine reuptake inhibition properties, leading to central nervous system (CNS) depression. Orphenadrine is an anticholinergic and antihistaminic agent with muscle relaxant properties, which also contributes to CNS depression. The concomitant use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of respiratory depression and sedation, and limit the duration of therapy. Educate patients and caregivers on the risks and symptoms of CNS depression.
For complete prescribing information:
View full ORPHENADRINE CITRATE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.